The current pandemic made scientists create new platforms of vaccines to fight against SARS-CoV-2. Without a doubt, the new forms of present vaccines could develop a diversity of unknown complications. Sputnik V vaccine with two different adenovirus vectors (Ad26 priming and Ad5 boost) was first announced safe and effective by Russia. However, there are controversies surrounding this vaccine such as the possible decline of its immunogenicity and diminished neutralizing capacity against some Covid-19 variants. In addition, its impression on serum biomarkers is not clearly surveyed. The present study aimed to evaluate the frequency of Sputnik V vaccine-related complications and its impression on inflammatory and hematologic biomarkers.
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Global Year
- Pain Management, Research and Education in Low- and Middle-Income Settings
- Sex and Gender Disparities in Pain
- Integrative Pain Care
- Translating Pain Knowledge to Practice
- Back Pain
- Prevention of Pain
- Pain in the Most Vulnerable
- Pain Education
- Joint Pain
- Pain After Surgery
- Global Year Campaign Archives
- My Letter to Pain
- IASP Statements
- ICD-11 Pain Classification
- Global Alliance of Partners for Pain Advocacy (GAPPA)
- National, Regional, and Global Pain Initiatives
- International Pain Summit
- Pain Awareness Month
- Global Year
- Careers
- About
- For Pain Patients and Professionals